120 related articles for article (PubMed ID: 38852057)
1. EXPRESSION OF SPP1 AND SPARC GENES IN TUMOR TISSUE OF PATIENTS WITH BREAST CANCER.
Chekhun V; Pavlova A; Zadvornyi T; Borikun T; Naleskina L; Mushii O; Bazas V; Lukianova N
Exp Oncol; 2024 May; 46(1):13-21. PubMed ID: 38852057
[TBL] [Abstract][Full Text] [Related]
2. EXPRESSION OF OSTEOPONTIN AND OSTEONECTIN IN BREAST AND PROSTATE CANCER CELLS WITH DIFFERENT SENSITIVITY TO DOXORUBICIN.
Zadvornyi T; Lukianova N; Borikun T; Gogol S; Virych P; Lykhova O; Chekhun V
Exp Oncol; 2022 Aug; 44(2):107-112. PubMed ID: 35964648
[TBL] [Abstract][Full Text] [Related]
3. Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer.
Schneider S; Yochim J; Brabender J; Uchida K; Danenberg KD; Metzger R; Schneider PM; Salonga D; Hölscher AH; Danenberg PV
Clin Cancer Res; 2004 Mar; 10(5):1588-96. PubMed ID: 15014008
[TBL] [Abstract][Full Text] [Related]
4. Relationship between the expression of the extracellular matrix genes SPARC, SPP1, FN1, ITGA5 and ITGAV and clinicopathological parameters of tumor progression and colorectal cancer dissemination.
Viana Lde S; Affonso RJ; Silva SR; Denadai MV; Matos D; Salinas de Souza C; Waisberg J
Oncology; 2013; 84(2):81-91. PubMed ID: 23128103
[TBL] [Abstract][Full Text] [Related]
5. EXPRESSION OF MARKERS OF BONE TISSUE REMODELING IN BREAST CANCER AND PROSTATE CANCER CELLS IN VITRO.
Lukianova N; Zadvornyi T; Kashuba E; Borikun T; Mushii О; Chekhun V
Exp Oncol; 2022 May; 44(1):39-46. PubMed ID: 35548963
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients.
Nagai MA; Gerhard R; Fregnani JH; Nonogaki S; Rierger RB; Netto MM; Soares FA
Breast Cancer Res Treat; 2011 Feb; 126(1):1-14. PubMed ID: 20369286
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms in matricellular SPP1 and SPARC contribute to susceptibility to papillary thyroid cancer.
Su X; Xu BH; Zhou DL; Ye ZL; He HC; Yang XH; Zhang X; Liu Q; Ma JJ; Shao Q; Yang AK; He CY
Genomics; 2020 Nov; 112(6):4959-4967. PubMed ID: 32919020
[TBL] [Abstract][Full Text] [Related]
8. Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma.
Dalla-Torre CA; Yoshimoto M; Lee CH; Joshua AM; de Toledo SR; Petrilli AS; Andrade JA; Chilton-MacNeill S; Zielenska M; Squire JA
BMC Cancer; 2006 Oct; 6():237. PubMed ID: 17022822
[TBL] [Abstract][Full Text] [Related]
9. Osteonectin (SPARC) prognostic value in prostate cancer.
Chekhun V; Borikun T; Zadvornyi T; Mushii O; Stakhovsky E; Vitruk Y; Lukianova N
Pathol Res Pract; 2024 Feb; 254():155053. PubMed ID: 38199134
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of SPP1/osteopontin expression as predictor of recurrence in tamoxifen treated breast cancer.
Göthlin Eremo A; Lagergren K; Othman L; Montgomery S; Andersson G; Tina E
Sci Rep; 2020 Jan; 10(1):1451. PubMed ID: 31996744
[TBL] [Abstract][Full Text] [Related]
11. SPP1 rs4754 and its epistatic interactions with SPARC polymorphisms in gastric cancer susceptibility.
Chen LZ; He CY; Su X; Peng JL; Chen DL; Ye Z; Yang DD; Wang ZX; Wang F; Shao JY; Xu RH
Gene; 2018 Jan; 640():43-50. PubMed ID: 28962925
[TBL] [Abstract][Full Text] [Related]
12. Association between SPARC mRNA expression, prognosis and response to neoadjuvant chemotherapy in early breast cancer: a pooled in-silico analysis.
Azim HA; Singhal S; Ignatiadis M; Desmedt C; Fumagalli D; Veys I; Larsimont D; Piccart M; Michiels S; Sotiriou C
PLoS One; 2013; 8(4):e62451. PubMed ID: 23638089
[TBL] [Abstract][Full Text] [Related]
13. FEATURES OF COL1A1 EXPRESSION IN BREAST CANCER TISSUE OF YOUNG PATIENTS.
Chekhun V; Mushii O; Zadvornyi T; Borikun T; Martyniuk О; Kashuba E; Kryzhanivska A; Andriiv A; Diakiv I; Lukianova N
Exp Oncol; 2023 Dec; 45(3):351-363. PubMed ID: 38186020
[TBL] [Abstract][Full Text] [Related]
14. Osteopontin level and promoter polymorphism in patients with metastatic breast cancer.
Elbaiomy MA; Akl T; Elhelaly R; El-Beshbishi W; El Ghonemy MS; Elzehery R
Curr Oncol; 2020 Oct; 27(5):e444-e450. PubMed ID: 33173383
[TBL] [Abstract][Full Text] [Related]
15. Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes.
Watkins G; Douglas-Jones A; Bryce R; Mansel RE; Jiang WG
Prostaglandins Leukot Essent Fatty Acids; 2005 Apr; 72(4):267-72. PubMed ID: 15763438
[TBL] [Abstract][Full Text] [Related]
16. The clinical significance of secreted protein acidic and rich in cysteine expression in breast cancer tissue and its association with prognosis.
Guo W; Zhang M; Chen Y; Guo S
J Cancer Res Ther; 2017; 13(5):833-836. PubMed ID: 29237913
[TBL] [Abstract][Full Text] [Related]
17. Correlation between secreted protein acidic and rich in cysteine protein expression and the prognosis of postoperative patients exhibiting esophageal squamous cell carcinoma.
Wu J; Zhang JR; Jiang XQ; Cao XG
Mol Med Rep; 2017 Sep; 16(3):3401-3406. PubMed ID: 28713937
[TBL] [Abstract][Full Text] [Related]
18. SPARC overexpression in primary tumors correlates with disease recurrence and overall survival in patients with triple negative breast cancer.
Zhu A; Yuan P; Du F; Hong R; Ding X; Shi X; Fan Y; Wang J; Luo Y; Ma F; Zhang P; Li Q; Xu B
Oncotarget; 2016 Nov; 7(47):76628-76634. PubMed ID: 27421134
[TBL] [Abstract][Full Text] [Related]
19. In phyllodes tumors of the breast expression of SPARC (osteonectin/BM40) mRNA by in situ hybridization correlates with protein expression by immunohistochemistry and is associated with tumor progression.
Kim NI; Kim GE; Lee JS; Park MH
Virchows Arch; 2017 Jan; 470(1):91-98. PubMed ID: 27909812
[TBL] [Abstract][Full Text] [Related]
20. Significant overexpression of SPARC/osteonectin mRNA in pancreatic cancer compared to cancer of the papilla of Vater.
Prenzel KL; Warnecke-Eberz U; Xi H; Brabender J; Baldus SE; Bollschweiler E; Gutschow CA; Hölscher AH; Schneider PM
Oncol Rep; 2006 May; 15(5):1397-401. PubMed ID: 16596217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
